(NASDAQ: HOWL) Werewolf Therapeutics's forecast annual revenue growth rate of 41.78% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Werewolf Therapeutics's revenue in 2024 is $16,221,000.On average, 3 Wall Street analysts forecast HOWL's revenue for 2024 to be $589,515,509, with the lowest HOWL revenue forecast at $291,150,959, and the highest HOWL revenue forecast at $1,173,294,909. On average, 2 Wall Street analysts forecast HOWL's revenue for 2025 to be $1,108,111,859, with the lowest HOWL revenue forecast at $43,455,367, and the highest HOWL revenue forecast at $2,172,768,350.
In 2026, HOWL is forecast to generate $2,172,768,350 in revenue, with the lowest revenue forecast at $2,172,768,350 and the highest revenue forecast at $2,172,768,350.